Crohn’s & Colitis Congress (CCC 2026)

Las Vegas, Nevada 22 January 2026 - 24 January 2026

Biologic + behavioural therapy shows favourable signals in CATHARSIS trial

24 Feb 2026 by

A novel therapeutic approach combining behavioural and biologic treatments appears feasible for the management of individuals with Crohn’s disease, based on feasibility and early outcomes from the CATHARSIS* trial.

Biologic + behavioural therapy shows favourable signals in CATHARSIS trial

24 Feb 2026

Should IBD patients avoid prescription NSAIDs?

19 Feb 2026 by

Despite the reported adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in individuals with inflammatory bowel disease (IBD), a study presented at Crohn’s and Colitis Congress 2026 appears to show otherwise.

Should IBD patients avoid prescription NSAIDs?

19 Feb 2026

Upadacitinib stays effective for 1 year in real-world UC patients

16 Feb 2026 by

Treatment with upadacitinib appears to yield high and durable remission rates in patients with ulcerative colitis (UC), according to 1-year data from a real-world study.

Upadacitinib stays effective for 1 year in real-world UC patients

16 Feb 2026

GLP-1 RAs bring a number of benefits in IBD

15 Feb 2026 by

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with inflammatory bowel disease (IBD) appears to result in favourable clinical outcomes, as shown in two retrospective studies.

GLP-1 RAs bring a number of benefits in IBD

15 Feb 2026

Advanced therapy does not affect time to pregnancy in women with IBD

14 Feb 2026 by

Exposure to advanced therapies, including biologics and small molecules, within 3 months of conception is not associated with an increase in time to pregnancy among women with inflammatory bowel disease (IBD), according to the WIsDoM* trial presented at the Crohn’s and Colitis Congress 2026.

Advanced therapy does not affect time to pregnancy in women with IBD

14 Feb 2026

Mirikizumab improves IBD outcomes during induction, maintenance periods

13 Feb 2026 by

Treatment with mirikizumab results in significant improvements in clinical, endoscopic, and histologic outcomes during induction and maintenance phases in patients with Crohn’s disease (CD) or ulcerative colitis (UC), according to an updated meta-analysis of randomized controlled trials (RCTs).

Mirikizumab improves IBD outcomes during induction, maintenance periods

13 Feb 2026

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

13 Feb 2026 by

Treatment with either vedolizumab or ustekinumab delivers significant and meaningful benefits to patients with Crohn’s disease (CD), but each has its distinct therapeutic profile with complementary advantages, reports a real-world study presented at CCC 2026.

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

13 Feb 2026